Abu Dhabi:Jamjoom Pharma, a prominent player in the regional pharmaceutical industry, has announced a partnership with Mubadala Bio's subsidiary Bioventure Healthcare (BVH) to expand patient access to Ustekinumab in the United Arab Emirates.
According to Wam, the agreement designates Jamjoom Pharma as the exclusive commercial arm for BVH's Ustekinumab product in the UAE. Jamjoom Pharma will lead compliant product commercialization and engagement with healthcare professionals, adhering to applicable regulatory requirements.
The collaboration combines BVH's pharmaceutical portfolio and quality capabilities with Jamjoom Pharma's established commercial presence, scale, and experience in engaging healthcare professionals across the UAE and the broader MEA region. This partnership underscores both organizations' commitment to enhancing patient access to specialty care and supporting the UAE's healthcare ecosystem.